Neurometrix Stock Performance
| NURO Stock | USD 4.38 0.01 0.23% |
NeuroMetrix has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.26, which conveys not very significant fluctuations relative to the market. As returns on the market increase, NeuroMetrix's returns are expected to increase less than the market. However, during the bear market, the loss of holding NeuroMetrix is expected to be smaller as well. NeuroMetrix right now secures a risk of 1.8%. Please verify NeuroMetrix sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to decide if NeuroMetrix will be following its current price movements.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in NeuroMetrix are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy basic indicators, NeuroMetrix is not utilizing all of its potentials. The newest stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (0.90) | Five Day Return (3.10) | Year To Date Return 11.45 | Ten Year Return (99.90) | All Time Return (100.00) |
Last Split Factor 1:8 | Dividend Date 2019-11-19 | Ex Dividend Date 2007-03-28 | Last Split Date 2023-11-22 |
1 | Incendia Therapeutics Names Healthcare Veteran Brad Smith as CFO, Brings 1B Financing Track Record - StockTitan | 12/03/2024 |
2 | NURO Stock Alert Halper Sadeh LLC Is Investigating Whether the Sale of NeuroMetrix, Inc. Is Fair to Shareholders | 12/18/2024 |
3 | SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates NURO, CARA, ARCH on Behalf of Shareholders | 12/19/2024 |
4 | Heres Why NeuroMetrix, Inc. Is Among the Best Diabetes Stocks to Buy Under 10 | 01/06/2025 |
5 | Disposition of 636 shares by Gozani Shai of NeuroMetrix at 4.31 subject to Rule 16b-3 | 01/31/2025 |
6 | Acquisition by Horowitz Joshua of 369 shares of NeuroMetrix subject to Rule 16b-3 | 02/03/2025 |
7 | Acquisition by Thomas Higgins of 469 shares of NeuroMetrix at 3.97 subject to Rule 16b-3 | 02/05/2025 |
| Begin Period Cash Flow | 4.3 M |
NeuroMetrix |
NeuroMetrix Relative Risk vs. Return Landscape
If you would invest 427.00 in NeuroMetrix on November 28, 2024 and sell it today you would earn a total of 11.00 from holding NeuroMetrix or generate 2.58% return on investment over 90 days. NeuroMetrix is currently generating 0.0591% in daily expected returns and assumes 1.795% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of stocks are less volatile than NeuroMetrix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NeuroMetrix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NeuroMetrix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NeuroMetrix, and traders can use it to determine the average amount a NeuroMetrix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0329
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | NURO | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.8 actual daily | 16 84% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average NeuroMetrix is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NeuroMetrix by adding it to a well-diversified portfolio.
NeuroMetrix Fundamentals Growth
NeuroMetrix Stock prices reflect investors' perceptions of the future prospects and financial health of NeuroMetrix, and NeuroMetrix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NeuroMetrix Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.04) % | ||||
| Operating Margin | (2.97) % | ||||
| Current Valuation | (5.7 M) | ||||
| Shares Outstanding | 2.05 M | ||||
| Price To Earning | 6.51 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 2.39 X | ||||
| Revenue | 5.9 M | ||||
| Gross Profit | 2.2 M | ||||
| EBITDA | (7.1 M) | ||||
| Net Income | (6.53 M) | ||||
| Cash And Equivalents | 20.83 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 240.88 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.79 X | ||||
| Book Value Per Share | 7.86 X | ||||
| Cash Flow From Operations | (6.08 M) | ||||
| Earnings Per Share | (4.51) X | ||||
| Market Capitalization | 8.99 M | ||||
| Total Asset | 21.42 M | ||||
| Retained Earnings | (210.11 M) | ||||
| Working Capital | 19.61 M | ||||
| Current Asset | 10.59 M | ||||
| Current Liabilities | 3.59 M | ||||
About NeuroMetrix Performance
By examining NeuroMetrix's fundamental ratios, stakeholders can obtain critical insights into NeuroMetrix's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that NeuroMetrix is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 262.16 | 275.27 | |
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.37) | (0.39) |
Things to note about NeuroMetrix performance evaluation
Checking the ongoing alerts about NeuroMetrix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NeuroMetrix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (6.53 M) with profit before overhead, payroll, taxes, and interest of 2.2 M. | |
| NeuroMetrix currently holds about 20.83 M in cash with (6.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68. | |
| NeuroMetrix has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Thomas Higgins of 469 shares of NeuroMetrix at 3.97 subject to Rule 16b-3 |
- Analyzing NeuroMetrix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NeuroMetrix's stock is overvalued or undervalued compared to its peers.
- Examining NeuroMetrix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NeuroMetrix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NeuroMetrix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NeuroMetrix's stock. These opinions can provide insight into NeuroMetrix's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.51) | Revenue Per Share | Quarterly Revenue Growth (0.51) | Return On Assets | Return On Equity |
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroMetrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.